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The task of the economy is to deliver and to enable prosperity […] our ability to flourish: 
physically, psychologically and socially.1 
 
These insights from Tim Jackson chime well with the work of Wilkinson and Marmot who 
highlight that: 
 
Societies that enable all citizens to play a full and useful role in the social, economic and 
cultural life of their society will be healthier than those where people face insecurity, 
exclusion and deprivation.2  
 
The evidence around addressing social factors related to health is robust and we have 
known about the importance of tackling these issues for many decades.  Despite this, most 
health and care systems invest most of their resources on biomedically oriented 
interventions at the expense of interventions that can address social factors related to 
health.3  In this manuscript we give an overview of approaches that could be used to 
increase allocation of resources to social prescribing, a class of health and care interventions 
that can address several social factors affecting health. 
 
 
Investing resources to promote population health 
 
Investment embodies one of the most vital relationships in economics – namely, the 
relationship between the present and the future […] Engaging in projects that last over time 
embodies our commitment to the future and is the basis for prosperity of any kind […] 
Investment is the vehicle through which we build, protect and maintain the assets on which 
tomorrow’s prosperity depends.1 
  
All investment decisions made by those responsible for allocating health and care resources 
have an impact.  Some of the impact is intended and some unintended; some positive, some 
negative (Figure 1).   
 
 Impact 
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Unintended 
(externalities) 
  
Figure 1. Impacts of Investments   
 
Layered onto investment decisions are also considerations of opportunity cost and creation 
of value – resources are limited by definition and if we invest them on things that do not 
deliver the highest value possible, with value in healthcare defined as delivering the best 
patient and population level outcomes while optimising resource utilisation4, we are not 
fulfilling our duty as stewards of the resource: 
The stewardship concept demands that we constantly ask the question: Will the resource be 
in better shape after my stewardship?5 
 
It is not a foregone conclusion that the economy that exists today must exist in perpetuity; 
the economy and the investment decisions we make within it are things we must imagine, 
design, plan and build so they meet our society’s needs.  Within the context of health and 
care systems we have traditionally seen a disproportionate amount of resources, both 
public/private and financial/non-financial resources, invested into the lifecycle of 
interventions that have their basis in the biomedical model.  It is well established that over-
reliance on the biomedical model, which focuses only on the biological roots of illness, 
prevents us from taking a holistic view of individuals and populations that accounts for 
lifestyle and wider social factors that are driving illness.7   
 
Why have we allowed this to happen?  Two underlying reasons are because of healthcare’s 
overreliance on the biomedical model and our, oftentimes, misguided views on Return on 
Investment (ROI). 
 
Firstly, the focus on just the biological aspects of illness begins upstream with research 
agencies who allocate far greater resources into basic science, translational and 
clinical/healthcare services research relative to understanding how to prevent disease, 
promote health and address social factors (for example, of the ~£2 billion distributed by the 
UK’s two largest health funding agencies, public health and prevention only account for ~2% 
of the UK National Institute for Health Research’s Research and Infrastructure budget8 and 
~4% of the UK Medical Research Council’s budget9, respectively).  There is much rhetorical 
weight given to statements like “an ounce of prevention is worth a pound of cure”, but 
disease prevention, health promotion and addressing social factors is complicated and 
requires that we take account of qualitative and contextual factors which is a contrast to the 
prevailing reductionist biomedical approach.  Further to this are considerations around 
timeframes to impact and attribution.  Because the biomedical model often time focuses 
mostly on symptom treatment, timeframes to impact are shorter and attribution is much 
more straightforward relative to helping an individual manage their condition or supporting 
them to prevent disease, improve their health and/or address social factors.   
 
Secondly, there is the larger issue of ROI.  The major focus of investments, whether public or 
private, has been to generate Financial ROI (F-ROI) and this drives investors to hold 
themselves accountable only to financial targets - indeed looking at the annual reports of 
two of UK largest health research funders attests to the importance of this.8, 9 For research 
funders, researchers, innovators, investors and healthcare payers, the prevailing ideology is 
that biomedical based interventions are the easiest means to a healthy FROI and savings.  
This misdirected pursuit of FROI leads to dangerous and unsustainable market distortions 
because of Intellectual Property Rights (IPR), Value Based Pricing (VBP) and financial 
engineering6 all at the opportunity cost of addressing important issues related to social 
factors of illness.   
 
Investing resources to promote population health: The essential role of social prescribing 
 
Social prescriptions provide “a way of linking patients in primary care with sources of 
support within the community to help improve their health and well-being.”10  Social 
prescriptions can address mental and physical health through activities like sports and 
leisure/arts and can address social factors through activities more focused on social issues 
(housing, food, etc.), education or skills development.11  If utilised properly, social 
prescriptions can deliver several benefits including addressing social factors, promoting self-
care and improving management of long-term conditions, all while optimising resource 
utilisation and contributing to better patient experience, satisfaction and outcomes.4  
 Though there has been a push to support the use of social prescriptions in the English NHS 
through the Universal Personalised Care Plan,12 the uptake and spread by commissioners, 
clinicians and patients has been limited and heterogenous as evidenced by a recent analysis 
that shows that in London alone, there were approximately 250,000 patients who could 
have benefited from a social prescription but didn’t receive one – something that could 
have resulted in £90 million in savings to the NHS.13   
 
A rate-limiting step in the more active use of social prescriptions is the availability of 
resources throughout the life cycle of social prescriptions, including research and evaluation 
to explore the design and delivery of more effective models as well as an assessment of 
their impact; private investment to facilitate the growth of social prescription providers and 
the creation of new technology to augment social prescriptions; and 
public/private/philanthropic funding models to support the social prescribing ecosystem.4   
 
Research & Evaluation 
The evidence base around social prescriptions is steadily growing but is not yet very robust.  
This is a challenge that could be readily addressed if research agencies allocated more 
funding to support the design and assessment of social prescriptions.  Further to this, 
research agencies will likely need to adopt more flexibility in the types of studies they fund 
because social prescriptions often need a process of continuous development, adjusting and 
testing.  This could actually be advantageous because unlike pharmaceutical and biotech 
interventions, social prescriptions can be rapidly modified so they can be tested through 
models like pragmatic control trials which are usually much less resource intensive, with 
regard to both time and money, than traditional randomised control trials.14   
 
Another advantage for social prescriptions is their ability to be easily augmented through 
technology. Leveraging IT (Artificial Intelligence (AI), machine learning, Internet of Things 
(IoT) and living services strategies) and Big Data (including the integration of -omics data) 
could see the agile development of technology-augmented social prescriptions that could 
disrupt the paradigm of how health and care are delivered.14   
 
Investment to grow innovations 
There is a significant opportunity for private investment into social prescriptions, 
particularly the technologies which can augment them.  Solow’s work has shown that 80% 
of economic growth can be explained through improvements in the use of technology,6 
which provides a powerful justification for more public research funding going towards the 
development and use of IT-augmented social prescriptions as well as for a greater 
proportion of private equity funding in healthcare to be allocated to this domain. 
 
Funding models to support the social prescribing ecosystem  
The English NHS allocates approximately £16 billion annually for pharmaceuticals.  Compare 
this to £44 million, a generous estimate of how much Clinical Commissioning Groups (CCGs) 
in England may have invested in social prescriptions from 2017-18 if we extrapolate the 
results of a survey of 55 CCGs.15   
 
There are some obvious reasons for this massive 350-fold greater investment in 
pharmaceuticals relative to social prescriptions – pharmaceuticals are the incumbent, there 
is more evidence for them and they fit into workflows which have been designed around 
their use. But this does not mean that we should simply accept the status quo because 
social prescribing, as highlighted above, has the potential to address many health-related 
issues that pharmaceuticals and other biomedical interventions will never be able to 
address.    
 
There are several funding models that could be used to support the social prescribing 
ecosystem but there is no one size fits all solution; the models used are very context-
dependent.  The table below gives an overview of some of the methods that have been 
used to fund the social prescribing ecosystem. 
 
  
  
Social Px Providers Social Px Prescribers 
FUNDING 
SOURCES 
 
 
Public 
 
 
 
-CCG funded social px 
providers 
-Local Authority funded 
social px providers 
-Combo CCG + LA co-funded 
-Personal Health Budgets*  
 
 
-CCG-funded link workers 
-Local Authority funded link 
workers 
 
 
 
 
Private 
-Individual out of pocket 
-Crowdfunding* 
 
-GP-practice funded link 
workers 
 
Philanthropic 
-Charities providing social px 
to patients 
-Foundations/philanthropies 
sponsoring social px 
providers 
 
-Foundations/philanthropies 
sponsoring link workers 
 
 
Table 1. Different funding models that could be used to support the social prescribing 
ecosystem (Social Px = social prescriptions; * indicate models which could theoretically be 
used to support the social prescribing ecosystem) 
Combo: public, private and/or philanthropic 
e.g. Social Impact Bond 
 Below we give some examples of how some of these schemes have been put into practice: 
 
Public funding 
- The Rotherham CCG directly funds the voluntary sector, which has led to major 
benefits for the local authority in relation to public health and social care services.16  
- The Newham CCG paid £4 per patient per class to providers to deliver a range of 
physical activity classes (gym sessions, Bollywood dance, Zumba, Quadro, yoga, Tai 
Chi, swimming, chair-based exercises, African dance, Line dance, Salsa, and 
Quadrille) in locations, like libraries, that were accessible to local residents.16 
 
Shared Investment 
- CCG + Local Authority: Exeter and East Riding in Yorkshire tested models that 
combine funding from CCGs and funding from community development, as well as 
adult and social care within local authorities. 
 
Combo Investment 
- Public + Private + Philanthropic: Ways to Wellness in Newcastle is a Social Impact 
Bond that has 22 Full Time Equivalents targeting 14,000 people with specific long-
term conditions which has demonstrated positive balance and generating savings for 
the NHS.17 
 
 
The way forward 
 Our current models of investment for health and care services leave much to be desired as 
highlighted by rising inequalities and decreasing life expectancies in high income countries 
including the UK.4  Social prescribing offer a promising solution to address many of the 
challenges we currently face and although recent commitments from the English NHS to 
increase investments in social prescribing are promising4, the scale of the challenge we face 
means that more thought, work, resources and risk-taking will be needed in the investments 
we make if we hope to address the unmet needs in our society and, more importantly, to 
tap into the potential we have as a wider health and care community to improve population 
health.   
 
Prosperity today means little if it undermines prosperity tomorrow. Investment is the vehicle 
through which we build, protect and maintain the assets on which tomorrow’s prosperity 
depends.1 
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